Tratamento da cisticercose subcutânea co praziquantel: um novo agente cestoidicida

Twenty adult patients presenting dermal cysticercosis without cerebral or ocular involvement were treated with praziquantel. The first eleven cases received 60 mg/kg/day and the last nine cases 30 mg/kg/day. In both groups the daily dose was split into three oral intakes 4 to 6 hours apart and the d...

Full description

Bibliographic Details
Main Author: Miroslau Constante Baranski
Format: Article
Language:English
Published: Universidade de São Paulo 1984-10-01
Series:Revista do Instituto de Medicina Tropical de São Paulo
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46651984000500006&lng=en&tlng=en
id doaj-d847ada187314187a8d7985595404dfc
record_format Article
spelling doaj-d847ada187314187a8d7985595404dfc2020-11-24T23:46:50ZengUniversidade de São PauloRevista do Instituto de Medicina Tropical de São Paulo1678-99461984-10-0126525926610.1590/S0036-46651984000500006S0036-46651984000500006Tratamento da cisticercose subcutânea co praziquantel: um novo agente cestoidicidaMiroslau Constante Baranski0Universidade Federal do ParanáTwenty adult patients presenting dermal cysticercosis without cerebral or ocular involvement were treated with praziquantel. The first eleven cases received 60 mg/kg/day and the last nine cases 30 mg/kg/day. In both groups the daily dose was split into three oral intakes 4 to 6 hours apart and the drug administration lasted for 6 consecutive days. The latter group of patients also got dexamethasone, 3 mg daily, from one day before until four days after the treatment period with praziquantel. The drug proved to be 100% efficacious as demonstrated histopathologically by the death of the cysticerci of Taenia solium (Cysticercus cellulosae) in serial biopsies taken from the 2nd week on after the end of treatment, as well as clinically by the steady disappearence of the dermal nodules during the 6 months following the therapy. Tolerance of praziquantel was good as the incidence and severity of side-effects were not relevant. The drug safety was confirmed through laboratory tests which failed to detect any abnormal findings related to the hematopoietic, liver and kidney functions.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46651984000500006&lng=en&tlng=en
collection DOAJ
language English
format Article
sources DOAJ
author Miroslau Constante Baranski
spellingShingle Miroslau Constante Baranski
Tratamento da cisticercose subcutânea co praziquantel: um novo agente cestoidicida
Revista do Instituto de Medicina Tropical de São Paulo
author_facet Miroslau Constante Baranski
author_sort Miroslau Constante Baranski
title Tratamento da cisticercose subcutânea co praziquantel: um novo agente cestoidicida
title_short Tratamento da cisticercose subcutânea co praziquantel: um novo agente cestoidicida
title_full Tratamento da cisticercose subcutânea co praziquantel: um novo agente cestoidicida
title_fullStr Tratamento da cisticercose subcutânea co praziquantel: um novo agente cestoidicida
title_full_unstemmed Tratamento da cisticercose subcutânea co praziquantel: um novo agente cestoidicida
title_sort tratamento da cisticercose subcutânea co praziquantel: um novo agente cestoidicida
publisher Universidade de São Paulo
series Revista do Instituto de Medicina Tropical de São Paulo
issn 1678-9946
publishDate 1984-10-01
description Twenty adult patients presenting dermal cysticercosis without cerebral or ocular involvement were treated with praziquantel. The first eleven cases received 60 mg/kg/day and the last nine cases 30 mg/kg/day. In both groups the daily dose was split into three oral intakes 4 to 6 hours apart and the drug administration lasted for 6 consecutive days. The latter group of patients also got dexamethasone, 3 mg daily, from one day before until four days after the treatment period with praziquantel. The drug proved to be 100% efficacious as demonstrated histopathologically by the death of the cysticerci of Taenia solium (Cysticercus cellulosae) in serial biopsies taken from the 2nd week on after the end of treatment, as well as clinically by the steady disappearence of the dermal nodules during the 6 months following the therapy. Tolerance of praziquantel was good as the incidence and severity of side-effects were not relevant. The drug safety was confirmed through laboratory tests which failed to detect any abnormal findings related to the hematopoietic, liver and kidney functions.
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46651984000500006&lng=en&tlng=en
work_keys_str_mv AT miroslauconstantebaranski tratamentodacisticercosesubcutaneacopraziquantelumnovoagentecestoidicida
_version_ 1725492089713590272